Nurix Therapeutics (NRIX) News
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.85-0.755 (-5.55%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NRIX news summary
We found 13 recent headlines mentioning Nurix Therapeutics (NRIX): 1 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire, Investing.com. NRIX is making an outsized move today, down 5.55% at $12.85, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "RHHBY Secures FDA Approval for Breast Cancer Treatment", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Nurix Therapeutics headlines
- RHHBY Secures FDA Approval for Breast Cancer TreatmentRoche wins FDA approval for Wilserdly plus everolimus, offering an all-oral treatment option for advanced breast cancer and strengthening its oncology portfolio.NasdaqNVS, NRIX
- Nurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical Development(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biotechnology company developing targeted protein degradation therapies, has appointed Dr. Arati V. Rao, M.D., as its new Chief Medical…NasdaqNRIX, HEI.A
- Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerPhysician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Physician-scientist and oncology leader…GlobeNewswire
- Nurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader Program(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, announced that Sanofi has decided to discontinue the Phase 1…NasdaqNRIX, SNY
- Why is Nurix Therapeutics stock collapsing 28% today?Investing.com
- Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today…GlobeNewswire
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesRoche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.NasdaqNVO, LLY, NRIX
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.NasdaqKYMR, ARVN, NRIX
- Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue(RTTNews) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major…Nasdaq
- Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58MSeeking Alpha
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLLGlobeNewswire
- Can KT-621 Mark a Turning Point for Kymera Therapeutics?KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.NasdaqKYMR, ARVN, NRIX
- Is Kymera Therapeutics Poised for a Breakthrough With KT-621?Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.NasdaqKYMR, ARVN, NRIX